Moderna Shares Slump Amid Concerns Over COVID-19 Vaccine Demand

The company stated that it’s ‘still too early’ to project vaccination rates for the full year.

The Moderna COVID-19 vaccination prepared at Lestonnac Free Clinic in Orange, Calif., on March 9, 2021. John Fredricks/The Epoch Times

Shares of pharmaceutical company Moderna have slumped again amid concerns about COVID-19 vaccine demand in the United States.

Over the past five days, shares of the company dropped about 18 percent, while over the past month, the stock has decreased by 20 percent. For all of 2023, meanwhile, shares of Moderna have plummeted by 54 percent.